XenoPort, Inc. – Product Pipeline Review – H2 2011

XenoPort, Inc. - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “XenoPort, Inc. - Product Pipeline Review - H2 2011” provides data on the XenoPort, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, XenoPort, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from XenoPort, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• XenoPort, Inc. - Brief XenoPort, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of XenoPort, Inc. human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of XenoPort, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the XenoPort, Inc.’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate XenoPort, Inc.’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of XenoPort, Inc. in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the XenoPort, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with XenoPort, Inc..
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of XenoPort, Inc. and identify potential opportunities in those areas.

Contents

XenoPort, Inc. Snapshot
XenoPort, Inc. Overview
Key Information
Key Facts
XenoPort, Inc. – Research and Development Overview
Key Therapeutic Areas
XenoPort, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
XenoPort, Inc. – Pipeline Products Glance
XenoPort, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
XenoPort, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
XenoPort, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
XenoPort, Inc. – Drug Profiles
Acomprosate Prodrug
Arbaclofen Placarbil
Horizant
XP-21279
XP21510
XP23829
XenoPort, Inc. – Pipeline Analysis
XenoPort, Inc. – Pipeline Products by Therapeutic Class
XenoPort, Inc. - Pipeline Products By Target
XenoPort, Inc. – Pipeline Products by Route of Administration
XenoPort, Inc. – Pipeline Products by Molecule Type
XenoPort, Inc. – Recent Pipeline Updates
XenoPort, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Horizant
XP20925
XenoPort, Inc. – Company Statement
XenoPort, Inc. – Locations And Subsidiaries
Head Office
Company's Recent Developments
XenoPort, Inc., Recent Developments
Apr 25, 2011: XenoPort Announces FDA Agreement On Special Protocol Assessment For Pivotal Phase III Clinical Trial Of Arbaclofen Placarbil For Spasticity In MS Patients
Mar 21, 2011: XenoPort Reports Results From Phase IIb Clinical Trial Of Arbaclofen Placarbil As Adjunctive Treatment For Patients With GERD
Apr 13, 2011: XenoPort Announces Presentation Of Preclinical Data For XP23829 At 63rd Annual Meeting Of American Academy of Neurology
Aug 09, 2011: GSK And XenoPort Submit Supplemental New Drug Application To FDA For Horizant In Postherpetic Neuralgia
Apr 06, 2011: GlaxoSmithKline And XenoPort Receive FDA Approval For Horizant
Financial Deals Landscape
XenoPort, Inc., Deals Summary
XenoPort, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
XenoPort Secures $25 Million In Series D Financing
XenoPort Secures $37 Million In Financing
Partnerships
XenoPort Amends Its Agreement With GlaxoSmithKline For Horizant
XenoPort Enters Into Co-Promotion Agreement With GlaxoSmithKline For Solzira
XenoPort Enters Into A Co-Development Agreement With Pfizer
Licensing Agreements
XenoPort Enters Into Licensing Agreement With Xanodyne
Astellas Pharma Enters Into Licensing Agreement With XenoPort
Equity Offering
XenoPort Prices An Underwritten Public Offering Of $31 Million
XenoPort Completes Public Offering Of $78.9 Million
XenoPort Completes Initial Public Offering Of $52.6 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

XenoPort, Inc., Key Information
XenoPort, Inc., Key Facts
XenoPort, Inc. – Pipeline by Therapy Area and Indication, H2 2011
XenoPort, Inc. – Pipeline by Stage of Development, H2 2011
XenoPort, Inc. – Monotherapy Products in Pipeline, H2 2011
XenoPort, Inc. – Filed, H2 2011
XenoPort, Inc. – Phase III, H2 2011
XenoPort, Inc. - Phase II, H2 2011
XenoPort, Inc. – Pre-Clinical, H2 2011
XenoPort, Inc. - Pipeline By Therapeutic Class, H2 2011
XenoPort, Inc. - Pipeline By Target, H2 2011
XenoPort, Inc. – Pipeline By Route of Administration, H2 2011
XenoPort, Inc. – Pipeline By Molecule Type, H2 2011
XenoPort, Inc. – Recent Pipeline Updates, H2 2011
XenoPort, Inc. - Discontinued Pipeline Products, 2010
XenoPort, Inc., Deals Summary
XenoPort Secures $25 Million In Series D Financing
XenoPort Secures $37 Million In Financing
XenoPort Amends Its Agreement With GlaxoSmithKline For Horizant
XenoPort Enters Into Co-Promotion Agreement With GlaxoSmithKline For Solzira
GlaxoSmithKline Enters Into An Agreement With XenoPort
XenoPort Enters Into A Co-Development Agreement With Pfizer
XenoPort Enters Into Licensing Agreement With Xanodyne
Astellas Pharma Enters Into Licensing Agreement With XenoPort
XenoPort Prices An Underwritten Public Offering Of $31 Million
XenoPort Completes Public Offering Of $55 Million
Xenoport Completes Private Placement Of $40 Million
XenoPort Completes Public Offering Of $78.9 Million
XenoPort Completes Initial Public Offering Of $52.6 Million

LIST OF FIGURES

XenoPort, Inc. – Pipeline by Therapy Area and Indication, H2 2011
XenoPort, Inc. – Pipeline by Stage of Development, H2 2011
XenoPort, Inc. – Monotherapy Products in Pipeline, H2 2011
XenoPort, Inc. – Pipeline By Therapeutic Class, H2 2011
XenoPort, Inc. – Pipeline By Molecule Type, H2 2011 Skip to top